Carbohydrate-binding agents (CBAs) have been proposed as innovative anti-HIV compounds selectively targeting the glycans of the HIV-1 envelope glycoprotein gp120 and preventing DC-SIGN-directed HIV capture by dendritic cells (DCs) and transmission to CD4 + T-lymphocytes. We now show that CBAs efficiently prevent R5 HIV-1 infection of human primary monocyte-derived macrophage (MDM) cell cultures in the nanomolar range. Both R5 and X4 HIV-1 strains were efficiently captured by the macrophage mannose-binding receptor (MMR) present on MDM. HIV-1 capture by MMR-expressing MDM was inhibited by soluble mannose-binding lectin and MMR antibody. Short pre-exposure of these HIV-1 strains to CBAs is able to prevent virus capture by MDM and subsequent syncytia formation in cocultures of the CBA-exposed HIV-1-captured MDM and uninfected CD4 + T-lymphocytes. The potential of CBAs to impair MDM in their capacity to capture and to transmit HIV to T-lymphocytes might be an important property to be taken into consideration in the eventual choice to select microbicide candidate drugs for clinical investigation.
Introduction
Antigen-presenting cells (APCs) [primary monocyte-derived macrophages (MDMs) and dendritic cells (DCs)] are a major target/reservoir for viral infection, and play an important role in activating the immune system. They process and present antigens for stimulation of primary and secondary T-cell responses in various forms by MHC class I and II pathways (Banchereau et al., 2001; Chougnet et al., 2002) . MDM and DC are known to express the CD4 receptor and are susceptible to infection with human immunodeficiency virus type 1 (HIV-1). MDM and DC may be the first cells in the subepithelial vaginal mucosa to be bound by, or infected with, HIV-1 during heterosexual transmission (Greenhead et al., 2000; Hu et al., 2000) . They are believed to act as reservoirs for virus replication and dissemination in all body compartments by their migratory capacity (Cameron et al., 1996) . While HIV-1 infection is associated with abnormalities in most compartments of the immune system, defects in cell-mediated immunity appear to be of clinical importance. Impaired APC function is thought to be a critical component of HIV-1-associated immunodeficiency (Chougnet, 2003; Donaghy et al., 2004) . Whereas immature DC are characterized by the presence of the C-type lectin DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-integrin) (Geijtenbeek et al., 2000) , MDM express another C-type lectin designated as macrophage mannose-binding receptor (MMR). The MMR is a 175-kDa transmembrane glycoprotein containing three distinct domains, two of which have carbohydrate-recognizing properties. The C-type lectin domains facilitate carbohydrate-dependent uptake of mannosylated protein antigens present on microorganisms including bacteria, yeast, enveloped viruses and protozoans (Reading et al., 2000) . The MMR shows high affinity for mannose and fucose, intermediate affinity for N-acetylglucosamine (GlcNAc) and glucose and low affinity for galactose (Stahl and Ezekowitz, 1998) . Because these terminal sugars are rarely found on the mammalian cell-surface, the MMR could be responsible for discrimination between self and non-self antigens (Engering et al., 1997) . It also plays a key role in pathogen-related acquired host defence by mediating antigen internalization and delivery to MHC class II compartments for antigen presentation (Engering et al., 1997; Tan et al., 1997) . Thus it is clear that both DC-SIGN on immature dendritic cells, and MMR on MDM can capture pathogens such as HIV, and present them to T-lymphocytes for further provoking a specific immune response. MDM contribute to the transmission and the pathogenesis of HIV-1 infection throughout the progression of HIV-1 infection especially at late stages of disease characterized by extensively depleted CD4 + T-lymphocyte pools (Badley et al., 1997; Herbein et al., 2002; Tomkowicz et al., 2006; Williams and Hickey, 2002) .
HIV-1 is an enveloped virus whose heavily glycosylated surface glycoprotein gp120 binds CD4 and a co-receptor of the target cell to initiate infection. A significant proportion of the gp120 glycosylation sites are highly (terminally) mannosylated, a pattern common to several other pathogens (Nguyen and Hildreth, 2003; Balzarini, 2007b) . Carbohydrate-binding agents (CBA) have been recently proposed as innovative anti-HIV compounds selectively targeting the glycans of the HIV-1 envelope glycoprotein gp120 (Balzarini, 2005) . Short pre-exposure of HIV-1 to CBAs prevents DC-SIGN to efficiently bind HIV-1 and prevent subsequent syncytia formation upon cocultivation of DC-expressing cells with T-lymphocytes . Indeed, the mannose-specific CBAs (i.e. the plant lectins HHA, GNA, NPA and CA; the procaryotic cyanovirin-N (CV-N)) and the GlcNAcspecific plant lectin UDA but not other entry inhibitors, nor polyanionic compounds, efficiently abrogate the DC-SIGN-directed HIV-1 capture and subsequent transmission to T-lymphocytes. Such compounds should have the potential to impair the ability of DC to capture HIV and to transmit the virus to T lymphocytes Fig. 1 . Inhibitory activity of test compounds against R5 HIV-1 (Ba-L) infection of MDM. MDM were exposed to various dilutions of the test compounds (30 min) prior to infection with HIV-1 (Ba-L) for 2 h. After several washing steps of the MDM cultures, new medium containing test compounds was added. The virus production was quantified by p24 ELISA at day 14 after the infection. . Thus, the CBAs differ from other types of entry inhibitors (i.e. the gp41 inhibitor enfuvirtide and the CXCR4 and CCR5 antagonists) that inhibit the transmission of the virus to T-cells in cocultivation assays of persistently HIV-1-infected cells and uninfected cells, but not the transmission of the virus through DC-SIGN-expressing cells (Balzarini, 2007a) . The aim of this study was to investigate the ability of CBAs to inhibit HIV-1 capture by MDM, one of the major cellular targets for HIV-1 infection and prominent virus reservoir, and to inhibit the subsequent virus transmission from HIV-1-captured MDM to CD4 + T-lymphocytes. Our data show that efficient HIV-1 capture occur by MDMs, which lack measurable expression of DC-SIGN but abundantly express the MMR. CBAs efficiently block the HIV capture by MDM and subsequent virus transmission to Tlymphocytes, a property that is beneficial from a microbicidal viewpoint.
Results

Antiviral activity of CBAs in HIV-1/BaL-infected MDM
MDM shortly (30 min) pre-incubated with several concentrations of CBAs were infected with HIV-1 BaL (3000 pg/ml) and supernatants were collected at days 7 and 14. The HIV-1 p24 ELISA analysis at day 14 revealed that CBAs are able to efficiently prevent HIV-1 BaL replication in MDM in a dosedependent fashion. Results are expressed as the percentage of the p24 values of the untreated controls, in which MDM were exposed to HIV-1 BaL in the absence of the CBAs (Fig. 1 ). The EC 50 (μM) and EC 90 (μM) values were shown in Table 1 . The geometric mean of p24 gag production was used to determine the effective drug concentration where 50% and 90% of viral replication is inhibited. A linear regression of the log percent HIV-1-p24 production (compared to untreated controls) versus the log of the drug concentration was plotted to calculate the EC 50 and EC 90 values. The mannose-specific plant lectin-derived HHA, GNA, CA and NPA, and the GlcNAc-specific UDA were markedly effective in inhibiting HIV-1 BaL p24 production in MDM (EC 50 values in the nanomolar range). The procaryotic mannose-specific cyanovirin-N (CV-N) proved exquisitely inhibitory to HIV-1/BaL infection of MDM (EC 50 in the higher picomolar range). The non-peptidic antibiotic PRM-A was inhibitory in the lower micromolar range and less effective than the plant lectin CBAs. In most cases, the inhibitory values in MDM were within the same order of magnitude as in T-lymphocytes (Table 1 ). The CBAs were not toxic to the MDM cultures at concentrations that were markedly higher than the antivirally effective concentrations (2 μM for HHA, GNA and NPA; 4 μM for CA; 10 μM for UDA; 60 μM for PRM-A; and 0.36 μM for CV-N).
Capture of various HIV-1 strains by B-lymphocyte Raji/DC-SIGN cells and MDM
Exponentially growing Raji/DC-SIGN cells and MDM were exposed to a variety of HIV-1 strains for 1 or 2 h, respectively. Then, the unadsorbed virus was carefully Fig. 2 . Capture of various HIV-1 strains by Raji/DC-SIGN cells and MDM in presence or in absence of CBAs. (A) Raji/DC-SIGN and MDM were exposed to several strains of HIV-1. After the time of infection, the cells were washed to be sure to remove the unbound virus. The Raji/DC-SIGN cell cultures and MDM were then analysed for p24 content by a p24 ELISA. (B) HIV-1 (NL4.3) particles were exposed to various dilutions of the test compounds (30 min) prior to administration to MDM for 2 h. After removal of unbound virus by several washing steps, cell-associated virus was qualified by p24 ELISA. Effective concentration or compound concentration required to inhibit HIV-1(BaL) p24 production in virus-infected monocyte-derived macrophages by 50% at day 14 post infection. b 90% Effective concentration or compound concentration required to inhibit HIV-1(BaL) p24 production in virus-infected monocyte-derived macrophages by 90% at day 14 post infection. c Minimal inhibitory concentration or compound concentration required to afford microscopically visible alteration of cell morphology upon visual inspection and trypan blue dye staining. d 50% Effective concentration or compound concentration required to inhibit HIV-1(III B )-induced cytopathicity in T-lymphocyte C8166 cell cultures at day 3 post infection (data taken from Balzarini et al., 2007a,b) . removed by several washing steps and the remaining HIV-1 p24, attached to the cells, determined by HIV-1 p24 ELISA. It should be mentioned that it would be unlikely that any HIV-1 (p24) was internalized into the Raji cells, since HIV-1-exposed control cultures of wild-type Raji/0 cells were p24-negative, and no evidence of productive virus infection of Raji/DC-SIGN was observed.
The results depicted in Fig. 2A represent the percentage of captured HIV-1 p24 compared with the initial input of HIV-1 p24 to the MDM. HIV-1 p24 associated with Raji/DC-SIGN cells and MDM could be reliably measured. HIV-1 NL4.3 was most efficiently captured (to the amount of ∼10% of input virus), whereas HIV-1 IIIB was the least efficiently captured (∼ 1% of input virus). When Raji/DC-SIGN and MDM were compared, for each individual virus strain, highly similar capture efficiencies were observed for DC-SIGN-expressing cells and MDM irrespective whether the virus represented an X4 or R5 isolate (correlation coefficient: r = 0.9) ( Fig. 2A ). Since the different stocks of the X4 HIV-1 strains were originally prepared in similar MT-4 cell cultures, we believe that differences in virus capture reflect differences in envelope glycans and structure, rather than differences in how the virions were prepared.
Inhibitory effect of CBAs on the ability of MDM to capture HIV-1 particles
To investigate whether CBAs may be useful as potential microbicide drugs, HIV-1 NL4.3 particles (100 μl; 67 × 10 3 pg/100 μl) were exposed to serial dilutions of the test compounds for 30 min. Then, the drug-exposed virus suspensions were added to MDM for 2 h at 37°C after which the cells were thoroughly washed with 1 ml RPMI-1640 (20% FBS) as described above. MDM were detached and then analyzed for p24 content by ELISA. The HIV-1 p24 content from the last wash supernatant was below detection limit. This revealed that unadsorbed virus particles in the medium were absent and that the HIV-1 p24 values solely represent virus amounts captured by the MDM. Data are expressed as a Fig. 3 . Effect of test compounds on the transmission of HIV-1 particles by MDM to C8166 cells. (A) Microscopic view of a 3-day coculture of uninfected C8166 cells + HIV-1 (NL4.3)-exposed MDM (the unadsorbed virus to the MDM was carefully removed after a 30-min incubation time prior to cocultivation of the MDM with the uninfected C8166 cells). (B) Microscopic view of a 3-day coculture of uninfected C8166 cells + MDM. HIV-1 (NL4.3) particles were exposed for 30 min to various dilutions of the test compounds (prior to administration to MDM for 2 h (C: UDA; D: NPA). After removal of unbound virus by several washing steps MDM were cocultivated with C8166 cells. The virus production was quantified by p24 ELISA after 3 and 4 days of coculture. percent of the p24 value of MDM control cultures that were incubated with HIV-1 NL4.3 in the absence of the CBAs.
The results show that the CBAs dose-dependently inhibited capture of HIV-1 NL4.3 by the MDM (Fig. 2B) . The mannosespecific NPA inhibited virus capture at an IC 50 of ∼ 0.4 μM whereas the IC 50 of the GlcNAc-specific UDA was ∼ 60 μM. The mannose-specific non-peptidic antibiotic PRM-A was also inhibitory to HIV-1 NL4.3 capture by MDM, albeit at a much higher drug concentration (Fig. 2B ).
Inhibitory effect of CBAs on the ability of MDM to transmit captured HIV-1 particles
Because MDM can capture HIV-1 particles and transmit HIV-1 to T-cells we wanted to investigate whether CBAs are able to prevent the transmission of the CBA-exposed virus particles from MDM to cocultured C8166 T-lymphocytes. As described for the virus capture, 67 × 10 3 pg of HIV-1 were exposed to serial dilutions of the test compounds for 30 min. CBA-exposed virus Fig. 4 . Effect of antibodies against the macrophage mannose receptor, DC-SIGN and CD4 on HIV-1 capture and transmission by MDM. MDM were incubated with 10 μg/ml MMR antibody, DC-SIGN antibody or CD4 antibody for 15 min at 37°C, after which HIV NL4.3 was added. After 2 h, MDM were thoroughly washed and detached for HIV-1 p24 capture analysis (A). For the transmission experiments, C8166 cells were added to antibody-treated HIV-1-exposed MDM and the analysis of HIV-1 p24 was done at days 3 and 4 after coculturing MDM with C8166 cells (B). (C) Microscopic view of a 3-day cocultures of uninfected C8166 cells + HIV-1 NL4.3exposed MDM (the unadsorbed virus in the MDM cultures was carefully removed after a 30-min incubation time prior to cocultivation of the MDM with the uninfected C8166 cells). (D, E, F) 3-day coculture of uninfected C8166 cells + HIV-1 exposed MDM pre-treated with specific CD4, DC-SIGN and MMR antibodies, respectively. suspensions were added to MDM for 2 h at 37°C after which the cells were thoroughly washed to remove excess of CBA and unbound virus. Then C8166 cells were added to the MDM cultures and cocultivated for 3 additional days. In a coculture of uninfected C8166 cells with HIV-1 NL4.3-exposed MDM, abundant giant cell formation and virus production is observed at day 3 after initiation of the cocultivation (Fig. 3A) . On the contrary, no syncytia were microscopically observed to appear in the C8166 coculture with uninfected MDM (Fig. 3B) . Interestingly, uninfected C8166 cells were predominantly clustered at the site of MDM locations in the cultures. The percentage of HIV-1 transmission was expressed as the percent of the p24 value of the positive control, in which MDM were exposed to HIV-1 NL4.3 that were not treated with CBAs. In the control cocultures (HIV-1-exposed MDM + C8166), significant amounts of HIV-1 p24 were produced. As shown in Fig. 3 , both UDA (C) and NPA (D) were able to markedly and dosedependently prevent the transmission of CBA-exposed HIV-1 from MDM to T-lymphocytes.
DC-SIGN and MMR expression in MDM cultures
We have examined the expression of DC-SIGN and MMR in MDM by flow cytometric analysis. MDM were stained with DC-SIGN and MMR antibodies and analyzed on a Becton Dickinson FACScan flow cytometer using CellQuest software. Flow cytometric analysis revealed that the MDM expressed MMR on their membrane (∼ 12% positive), whereas very little, if any expression of DC-SIGN (b 1% positive) was observed. This indicates that the latter C-type lectin receptor does not significantly contribute to the HIV-1 binding to MDM.
Role of the macrophage mannose receptor, DC-SIGN and CD4 on HIV-1 capture and subsequent transmission by MDM
To study the role of MMR in the capture and transmission of HIV-1, the effect of an anti-MMR antibody was compared with antibodies directed against several other receptors. MDM were incubated with anti-MMR antibody (10 μg/ml), anti-DC-SIGN antibody (10 μg/ml), and anti-CD4 antibody (10 μg/ml), for 15 min at 37°C. HIV NL4.3 (67 × 10 3 pg/100 μl) was then added to the MDM and exposed for 2 h at 37°C. Cells were washed and detached for HIV-1 p24 capture analysis (Fig. 4A ). For the transmission experiments, C8166 cells were added to antibodytreated MDM and the analysis of HIV-1 p24 was determined at day 3 after coculturing HIV-1-exposed MDM with C8166 cells (Fig. 4B ). The percentage of captured and transmitted HIV-1 was expressed as a percentage of the value of the positive control, in which MDM were incubated without CBAs.
The MMR antibody proved able to prevent both HIV-1 particle capture by MDM and subsequent virus transmission to C8166, while CD4 and DC-SIGN antibodies do not prevent these events. These observations show the importance of MMR but not DC-SIGN or CD4 in the capture and the transmission of HIV-1 particles from MDM to T-lymphocyte cells.
Thus, the ability of anti-MMR antibody to inhibit virus capture and subsequent virus transmission to T cells further supports the idea that the interaction of HIV-1 with MDM is predominantly MMR-mediated.
These findings were confirmed by microscopic evaluation (Figs. 4C-F) . In fact, we could show that the anti-MMR antibody (panel F) completely prevented syncytia formation in HIV-1-exposed MDM cell cultures cocultured with C8166 (panel C). In contrast, the presence of anti-CD4 (panel D) or anti-DC-SIGN (panel E) antibodies did not prevent this cytopathic effect.
Inhibitory effect of mannan on the ability of MDM to capture HIV-1
To further confirm the role of MMR in HIV capture by MDM we added mannan (at 2.5 mg/ml) to the MDM cultures. Two different procedures were used: (i) the mannan was added to MDM for 15 min at 37°C and then the virus was added (67 × 10 3 pg/100 μl for 2 h at 37°C), and (ii) the mannan was mixed with the virus (67 × 10 3 pg for 15 min at 37°C) and then the mannan/virus mixture was exposed to MDM for 2 h at 37°C. Then the cells were thoroughly washed to remove free unbound virus and mannan. As evident from Fig. 5 , mannan was able to partially prevent the HIV-1 NL4.3 capture by MDM under both experimental conditions.
Discussion
Studies have shown that MDM and DC are among the very first cells in the subepithelial vaginal mucosa to be bound by, or infected with, HIV during heterosexual transmission (Greenhead et al., 2000; Hu et al., 2000; Miller and Shattock, 2003) . Given the fact that MDM express high levels of MMR (Linehan et al., 1999) and the abundance of exposed mannose residues on the HIV gp120 envelope (Mizuochi et al., 1988; Zhu et al., 2000) , studies on the interactions between HIV and this receptor could offer insights into some of the first steps of infection following mucosal viral exposure. We found that a variety of different HIV-1 strains could be efficiently captured by MDM. The efficiency of virus capture depended on the nature of the virus isolate. It should be Fig. 5 . Inhibitory effect of mannan on the ability of MDM to capture HIV-1. Mannan (2.5 mg/ml) was added to the MDM cultures by two different procedures: (i) the mannan was added to MDM for 15 min at 37°C and then the virus was added; (ii) the mannan was mixed with the virus and then the mannan/ virus mixture was exposed to MDM. After 2 h, MDM were washed and analysed for the captured p24.
noticed that MDM often captured X4 strains more efficiently than the R5 HIV-1 strains, as shown in Fig. 2 in which HIV-1 BaL (R5) is captured at a ∼10-fold lesser efficiency as for example HIV-1 NL4.3 (X4). However, in contrast with R5 virus, a significant productive infection of MDM with X4 strains is never observed (as revealed by comparative p24 analysis at 14 days after HIV-1 R5 or X4 infection). Thus, virus capture by MDM and subsequent productive virus infection of the MDM are two separate events. MDM cultures exposed to X4 HIV-1 and cocultivated with uninfected C8166 for as few as 3-4 days showed a markedly increased HIV-1 p24 production, in contrast with MDM exposed to X4 HIV-1 but not cocultivated with C8166 cells. MDM could indeed efficiently transmit captured HIV-1 particles to uninfected T-lymphocytes, resulting in a productive infection of the T-lymphocytes and subsequent abundant syncytia formation. This pronounced virus transmission efficiency by MDM proved still inferior to the rate of virus transmission from HIV-1-captured Raji/DC-SIGN cells to T-lymphocytes. Indeed, abundant virus production and syncytia formation in C8166 cell cocultures and concomitant HIV-1 p24 production occur at least 1 day earlier in cocultures of HIV-captured Raji/DC-SIGN with C8166 cells when compared with cocultures of virus-captured MDM with C8166 cells and data not shown). Thus, although the efficiency of capturing of the different HIV-1 strains by MDM closely paralleled capture efficiency by DC-SIGN (Fig. 2) , our observations suggest that virus transmission of captured virus particles by DC-SIGN-expressing dendritic cells may be more efficient than virus transmission by MMR-expressing macrophage cells. Since we could also demonstrate that the MDM cultures express significant levels of MMR but not DC-SIGN, we may conclude that HIV capture by MDM and subsequent transmission to T-lymphocytes might be most likely directed by MMR. The inhibitory effect of the anti-MMR antibody but not the anti-DC-SIGN and anti-CD4 antibody against HIV-1 capture by MDM, further support the instrumental role of MMR in virus capture (and subsequent transmission) of HIV by MDM.
If CBAs such as the mannose-specific plant lectins HHA, GNA, NPA, CA, the mannose-specific non-peptidic antibiotic PRM-A, or the GlcNAc-specific UDA are present in the environment of the virus, they may bind to the glycans of gp120, preventing efficient capture of the virus by the MMR of MDM. The observation that UDA is effective in inhibiting HIV capture by MDM, at a lesser efficiency than the mannose-specific CBA, can be explained by the reported lower affinity of MMR for GlcNAc compared with mannose (Zamze et al., 2002) . The lower efficiency of the non-peptidic PRM-A on MMR-directed HIV-1 capture than the lectins might be explained by a lower affinity of PRM-A to gp120 than the lectins. This has indeed recently been demonstrated for HHA versus PRM-A .
We believe that our findings are relevant to be taken into account in the choice and development of (novel) candidate microbicide drugs. Indeed, during sexual intercourse, the very first sites of interaction of HIV in the infected individual are thought to be predominantly immature DCs that are present in the vaginal mucosa, but also MDM. The C-type mannose-specific lectins DC-SIGN and MMR may function as efficient receptors responsible for the capture of HIV through interaction with the glycans of HIV gp120. The findings that CBAs efficiently prevent the virus capture and subsequent transmission to CD4 + T-lymphocytes by MDM (and DC-SIGN)-expressing cells and that the CBA not only prevent capture of X4 HIV-1 strains by MDM but also prevent productive R5 HIV-1 replication in MDM, may make CBAs instrumental in preventing the establishment of new infections through sexual intercourse. However, recently, it was reported that langerin, a C-type lectin that is present in epithelial Langerhans cells (LC), prevents HIV-1 transmission by internalization of captured HIV particles and subsequent intracellular degradation (de Witte et al., 2007) . Although such as mechanism may be efficient for a first-line inactivation of HIV, CBA-exposed HIV strains may perhaps decrease the efficiency of LC to eliminate HIV, but at the same time may also compromise the ability of the virus to be efficiently transmitted by DC and MDM as well. In vivo models (i.e. SIV-infected monkeys) may reveal the relative importance of the effect of CBAs on the virus capture/transmission/inactivation by the different cell types.
Materials and methods
Test compounds
The mannose-specific plant lectins from Hippeastrum hybrid (HHA), Galanthus nivalis (GNA), Narcissus pseudonarcissus (NPA), Cymbidium agglutinin (CA) and the GlcNAc-specific plant lectin from Urtica dioica (UDA) were derived and purified from these plants, as described before (Van Damme et al., 1987 , 1992 . Pradimicin A (PRM-A) (MW 838) was isolated and purified from the fermentation broth of Actinomadura hibisca and kindly provided by Dr. Y. Igarashi. Cyanovirin (CV-N) was kindly provided by Dr. JB McMahon (National Institutes of Health, Bethesda, MD) and Dr. A Bolmstedt (Göteborg, Sweden). Mannan (from Saccharomyces cerevisiae) was from Sigma (MO).
Cells
Human T-lymphocytic C8166 cells were obtained from the American Type Culture Collection (Manassas, VA). Exponentially growing B-lymphoblast DC-SIGN-expressing Raji/DC-SIGN cells (Raji/DC-SIGN) were constructed by Geijtenbeek et al. (2000) and kindly provided by Dr. L Burleigh (Institut Pasteur, Paris, France). All cell lines mentioned were cultivated in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (BioWittaker Europe, Verviers, Belgium), 2 mM L-glutamine and 0.075 M NaHCO 3 . MDM were obtained from the blood of healthy seronegative donors by separation over a Ficoll-Hypaque gradient as previously described (Aquaro and Perno, 2005) . Briefly, peripheral blood mononuclear cells (PBMC) were seeded in 48-well plates at 1.8 × 10 6 cells/well in 1 ml of RPMI 1640 medium containing 20% heat-inactivated endotoxin and mycoplasma-free fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT), 4 mM L-glutamine (Life Technologies), 50 U/ml penicillin and 50 μg/ml streptomycin (Life Technologies) (hereinafter referred to as complete medium). Six days after plating and culturing the PBMC at 37°C in a humidified atmosphere enriched with 5% CO 2 , non-adherent cells were carefully removed by repeated washings with warm RPMI-1640 medium, leaving a monolayer of adherent cells which were eventually incubated in complete medium. Cell cultures treated under these experimental conditions have been shown to consist of N97% MDM, as determined by cytofluorimetric analyses (Aquaro et al., 2000) . 
Antiviral effect of CBAs against HIV-1 BaL infection of MDM
MDM, obtained from blood of seronegative donors, were pretreated for 30 min with several concentrations of CBAs, and infected with 3000 pg/ml of HIV-1 BaL. After 2 h of infection, the medium was removed, the cells were washed four times with RPMI-1640, and the MDM further cultured in the presence of the CBAs. At day 7, the supernatants were collected, and CBAcontaining fresh medium added to the new medium. At 14 days, the supernatants were collected and tested for p24 antigen production by p24 ELISA (Perkin Elmer, Boston, MA). Each experiment was run in triplicate.
The geometric mean of p24 gag production of replicates in each experiment was used to determine the effective drug concentration where 50% and 90% of viral replication was inhibited (representing the EC 50 and EC 90 , respectively), by linear regression of the log of the percent HIV-1-p24 production (compared to untreated controls) versus the log of the drug concentration.
HIV-1-capture by Raji/DC-SIGN cells and MDM
Raji/DC-SIGN cells were suspended in cell culture medium at 6 ×10 6 cells/400 μl. 0.4-ml suspensions of Raji/DC-SIGN cells were exposed to 0.6 ml HIV-1 for 60 min, after which 39 ml of culture medium was added to the virus-infected cell culture. The cells were centrifuged at 1250 rpm for 10 min, and 39.9 ml supernatant carefully removed. The virus-exposed cells were then resuspended in 39.9 ml medium. After a second centrifugation step, 39.9 ml supernatant was again removed, and the remaining 0.1 ml cell suspension was 10-fold diluted in cell culture medium (1 ml). Under these experimental (washing) conditions, a maximum of 8 pg HIV-1 p24 could have remained in the 1 ml supernatant (or 0.4 pg in 50 μl). The Raji/DC-SIGN cell cultures were then analysed for p24 content by a p24 ELISA (Perkin Elmer).
MDM obtained by Ficoll-Hypaque from the blood of seronegative donors were exposed to 100 μl of HIV-1 for 2 h after which 4 washes with RPMI-1640 medium (20% FBS) were performed to remove the unbound virus. To confirm the efficient removal of unbound virus, we collected 100 μl from the last wash to be analyzed by p24 ELISA (Perkin Elmer). Then, the MDM were detached from the plates and analyzed for captured HIV-1 p24 by a HIV-1 p24 ELISA. The percentage of captured p24 HIV-1 (pg/ml) was calculated compared with the initially administered HIV-1 p24 (pg/ml).
Effect of short exposure of HIV-1 to the CBAs on HIV-1-capture by MDM HIV-1 was pre-exposed to several dilutions of the CBAs for 30 min at 37°C. Then drug-exposed virus suspensions (HIV-1 NL4.3 67 × 10 3 pg in 100 μl) were added to MDM for 2 h at 37°C. After the incubation period, the virus was removed and the cells were carefully washed four times with RPMI-1640 (20% FBS), to remove the unbound virus in the wells. To confirm the efficient removal of unbound virus, we collected 100 μl from the last wash to be analyzed by a p24 ELISA (Perkin Elmer). Then the cells were detached from the wells and collected to analyze the HIV-1 p24-capture by ELISA test.
Effect of short exposure of HIV-1 to CBAs on virus transmission from MDM to T-lymphocyte cells
Human T-lymphocyte C8166 cells (100 × 10 3 cells/well in 1 ml RPM-1640 (10% FBS)) were added to CBA-exposed HIV-1captured MDM (prepared as described above). We then determined the HIV-1 transmission from virus-captured MDM to C8166 cells by analyzing the HIV-1 p24 production by ELISA in the supernatants from the cocultures at 3 and 4 days post cocultivation.
Flow cytometric analysis
To analyze the dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN) and macrophage mannose receptor (MMR) expression on MDM, the cells were stained with anti-DC-SIGN (DCN46-FITC; BD Biosciences) and anti-MMR (CD206-PE; BD Biosciences) and the samples processed for flow cytometric analysis as previously described (Vermeire et al., 2003) .
Effects of anti-CD4, -MMR and -DC-SIGN antibodies and mannan on HIV-1 capture by MDM and subsequent transmission to T lymphocytes MDM were pre-incubated with antibodies (anti-macrophage mannose receptor (MMR) antibody CD206, BD Pharmingen: 10 μg/ml; anti-DC-SIGN antibody, BD Pharmingen: 10 μg/ml; anti-CD4 antibody, BD Pharmingen: 10 μg/ml) for 15 min at 37°C. HIV NL4.3 (67 × 10 3 pg/100 μl) was then added and incubated for 2 h at 37°C. For the mannan administration, we used two different procedures: (1) mannan (2.5 mg/ml) was added to MDM for 15 min at 37°C after which the virus (67 × 10 3 pg/100 μl) was added for 2 h at 37°C; and (2) mannan (2.5 mg/ml) was mixed with virus (67 × 10 3 pg/100 μl) for 15 min at 37°C and then added to MDM for 2 h at 37°C. Cells were washed four times with RPMI-1640 (20% FBS) to remove unbound virus, and the cells were detached from the wells and collected to analyze the captured HIV-1 p24 by ELISA. For the HIV-1 transmission experiment, MDM were further cocultured with C8166 cells for 3 or 4 days and then supernatants were analyzed to determine virus transmission (replication) to the C8166 cells.
CBA toxicity
To assess the CBA toxicity in the MDM cultures, we used three uninfected cell culture controls in which the MDM were treated with different concentrations of CBAs and cell viability of the MDM analysed after 14 days of culture. The analysis was obtained by light microscopy and the trypan blue dye exclusion method.
Statistical analysis
The experiments were carried out in triplicate, with six positive controls (untreated virus-infected cells) for each experiment, and the results are presented as mean values with standard deviation.
